Today: 11 June 2026
Salesforce stock slips after-hours to end 2025 as focus turns to Agentforce AI and Feb. 25 earnings

Salesforce stock slips after-hours to end 2025 as focus turns to Agentforce AI and Feb. 25 earnings

NEW YORK, December 31, 2025, 19:03 ET — After-hours

  • Salesforce fell 0.4% to $264.91, little changed in extended trade
  • Wall Street ended the year’s final session lower, led by tech weakness
  • Investors now look to Agentforce AI traction and Salesforce’s next earnings date

Salesforce, Inc. shares ended down 0.4% on Wednesday and hovered near $264.91 in after-hours trading, as the cloud software maker closed out 2025’s final session on a subdued note. The stock traded between $264.44 and $266.12 during the session.

The late drift underscored how thin year-end liquidity can magnify moves in large-cap technology names, even without fresh company news.

For Salesforce, the timing matters because investors are resetting exposure ahead of 2026, when spending on enterprise software and new AI features is expected to be under sharper scrutiny.

A Yahoo Finance report earlier on Wednesday highlighted a 330% year-on-year jump in annual recurring revenue for Salesforce’s Agentforce offering, to about $540 million. Annual recurring revenue is the run-rate value of subscription contracts.

Salesforce sells customer relationship management software — tools that help companies track sales leads and manage customer service — and has been pushing customers toward add-on AI features, including “AI agents” designed to take actions such as drafting emails or updating records.

Wall Street ended the year’s final session lower, with the S&P 500 down 0.74% and the Nasdaq off 0.76%, Reuters reported, as tech shares weighed on benchmarks. “I do not expect that the last few days will have so much bearing on the performance of the next year,” said Giuseppe Sette, co-founder and president of Reflexivity, citing profit-taking when liquidity was low. Markets are closed Thursday for New Year’s Day. Reuters

In enterprise software, Microsoft fell 0.8%, Oracle slid 1.2% and ServiceNow dropped 0.7%, keeping pressure on the group.

Salesforce last updated investors on Dec. 3, when it raised its fiscal 2026 revenue and adjusted profit forecasts on stronger demand for its AI agent platform, Reuters reported.

That guidance sets the bar for 2026, when investors will look for AI-driven growth to show up in paid subscriptions while margins hold up.

The next major checkpoint is the company’s quarterly report expected on Feb. 25, 2026 after the bell, according to Yahoo Finance’s earnings calendar, with analysts looking for about $3.05 per share in profit.

Until then, traders are likely to focus on updates around Agentforce deal wins, renewals and operating margins, along with any new partnerships that broaden Salesforce’s reach in enterprise AI.

Stock Market Today

  • AMD Stock Price Forecast: Analyst Lowers Target Amid AI Market Caution
    June 11, 2026, 11:00 AM EDT. Shares of Advanced Micro Devices (AMD) have surged 111% year-to-date, driven by investor optimism over its expanding role in the artificial intelligence (AI) sector. Despite the strong performance, a prominent AI-focused analyst has trimmed the price target for AMD, signaling caution about the chipmaker's near-term prospects. The analyst cited concerns over competitive pressures and potential market saturation. AMD's growth is largely tied to its ability to capture demand in AI computing, a fast-evolving field requiring specialized semiconductor technology. Investors are weighing the company's robust sales against risks from supply chain constraints and intensifying industry competition.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Why FICO Stock Is Sliding Today: Fair Isaac Drops in Thin Year-End Trading
Previous Story

Why FICO Stock Is Sliding Today: Fair Isaac Drops in Thin Year-End Trading

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD
Next Story

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

Go toTop